All episodes

320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

From "Say More": What Happens When AI Decides Your Medical Coverage

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

318: Drug pricing drops & psychedelics under fire

317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

313: Biotech layoffs, founder-focused VC, & a big pharma exit

312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review

310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)

309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

308: An ASCO preview & another Duchenne trial failure

307: More tumult at BIO & coercive care for sickle cell patients

306: Live! From the STAT Breakthrough Summit West

305: Everything you need to know about H5N1 bird flu

304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

302: Vertex's big deal, biotech's red numbers, & an industry history lesson

301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

299: Live! From the STAT Breakthrough Summit East

298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

297: VC turmoil, GLP-1 competition, & the war on recovery

296: Legal insider trading, booming biotech stocks, & the next GLP-1

295: Humira’s legacy, CEO symbolism, and genomic surgery

294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

293: AI in medicine, detangling hype, and Icelandic DNA

292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

291: The plight of the VC, Gilead's latest setback, & more M&A

290: Biotech layoffs, slumping stocks, and a 2024 preview

289: Live! From #JPM24

287: 2023 in review, CEO report cards, and a look at the year ahead

286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

285: CRISPR history, biotech struggles, & a big week for deals

284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

283: A CRISPR milestone, algorithms amok, & biotech mixology

From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

279: Live from the 2023 STAT Summit

278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

275: A thorny ALS debate at the FDA, and the promise of artificial wombs

274: Covid’s latest surge, Alnylam at the FDA, & the end of an era

273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

272: Vivek's star turn, leaky drug data, & biotech as family business

271: Racing for gene therapy, a pioneering approval, & startups in the lurch

270: Your guide to Wegovy’s blockbuster heart study

269: Biotech layoffs, eye drug drama, & gene therapy milestones

268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

264: Messy PBM conflicts, debatable vaccines, & the future of flu season

263: Biogen's messy board, Laronde's data problem, & the downside of a boom

262: Merck v. USA, the best of ASCO, and Leqembi at the FDA

261: Fake medical devices, real cancer drugs, & curious Ozempic effects

260: ChatGPT in medicine, a boom in weight loss pills, & Sarepta at the FDA

259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

257: Lilly's Alzheimer's success, a milestone FDA approval, & Moderna's shrinking business

256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval

255: Sarepta's pivotal moment, biotech's big week, & the future of Covid boosters

254: The legal battle over abortion, an FDA 'bully pulpit' and Moderna's future

253: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers

252: Biotech's monkey shortage, the broken generics market, & conference cancel culture

251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster

250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina

249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

248: The next CRISPR fight, cheaper insulin, & an FDA shuffle

247: Vertex vs. insurers, Moderna's future, & biotech's long winter

246: Vas Narasimhan on the future of pharma, plus Moderna’s promise & a biotech presidential bid

245: The return of bird flu and the effects of pandemic fatigue

244: Pharma blockbusters, pandemic policy, & legal chicanery

243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection

242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score

241: #JPM23 in review, the year ahead, & the merits of Miami

240: #JPM23, the future of Alzheimer's, & rising Covid variants

239: 2022 in review, CEO indictments, & the year ahead

238: Leaky health data, ASH22, & what it takes to get booed by your peers

237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

235: LIVE from the STAT Summit

234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

233: How the biotech revolution could come apart at the seams

232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market

230: BIO's messy transition, mRNA's future, & Biogen's next CEO

229: Nobels for science, biotech dealmaking, & a friendly FTC

228: A surprise success in Alzheimer's and how FDA history seeded modern controversy

227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0

226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred

225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO

222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment